Skip to main content

Table 1 Inclusion and exclusion criteria

From: Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial

Inclusion criteria:

  Age ≥ 18 years

  TIA, amaurosis fugax or minor ischemic stroke (mRS ≤ 3)

  Symptom onset < 6 months

  Impaired glucose tolerance (2-hour post-load glucose level between 7.8 and 11.0 mmol/L) in 2 consecutive measurements

Exclusion criteria:

  Diabetes mellitus

  History of diabetic ketoacidosis

  Symptoms of type 1 diabetes

  Signs of renal impairment (creatinine of 135 μmol/L or higher for men, and 110 μmol/L or higher for women)

  Known liver disease or disturbed liver function tests (alanine amino transferase, aspartate amino transferase, alkaline phosphatase, or γ-glutamyl transferase increased to more than twice the upper limit of typical values)

  History of lactic acidosis

  Heart failure requiring pharmacological therapy

  Pancreatitis

  Chronic hypoxic lung disease stages III–IV

  Digoxin use

  Pregnancy or breastfeeding

  1. mRS modified Rankin Scale, TIA transient ischemic attack